



ACIP Pneumococcal Vaccine Recommendations Adults Aged ≥65 years and Adults Aged 19-64 years With a Risk Condition

Adults who are Pneumococcal conjugate vaccine (PCV) naïve



* Adults with Immunocompromising conditions, cochlear implants, or CSF leak might benefit from shorter intervals of ≥8 weeks.

Adults with previous PPSV23 only




**See [Morbidity and Mortality Weekly Report \(Vol. 71 / No.4\) Table 1](#) for qualifying risk conditions.

Adults who previously received PCV13

The incremental public health benefits of providing PCV15 or PCV20 to adults who have received PCV13 only or both PCV13 and PPSV23 have not been evaluated.



For those adults who have received PCV13 with or without PPSV23, CDC recommends following the previous guidance for [Pneumococcal Vaccine Timing in Adults](#) (High level guidance is summarized here).



CDC does not currently have a policy preferentially recommending PCV15 or PCV20 in adults who have received PCV13.

† For Adults who have received PCV13 but have not completed their recommended pneumococcal vaccine series with PPSV23 – one dose of PCV20 may be used if PPSV23 is not available.